Patents by Inventor Andrew R. Blight

Andrew R. Blight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
    Publication number: 20150080436
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Application
    Filed: November 3, 2014
    Publication date: March 19, 2015
    Inventors: Andrew R. Blight, Ron Cohen
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CNS INJURIES
    Publication number: 20140248253
    Abstract: The present invention is directed to a method of improving functional recovery following a central nervous system contusion injury. The method includes administering a therapeutically effective amount of glycosaminoglycan degrading enzyme. The glycosaminoglycan degrading enzyme may be dermatan sulfate or chondroitin sulfate degrading enzymes. The central nervous system contusion injury may include a traumatic brain injury or a spinal cord injury. The functional recovery may include autonomic functions, sensory functions, motor functions or the like.
    Type: Application
    Filed: January 30, 2014
    Publication date: September 4, 2014
    Applicant: ACORDA THERAPEUTICS, INC.
    Inventors: Elliott A. GRUSKIN, Anthony O. CAGGIANO, Michael P. ZIMBER, Andrew R. BLIGHT
  • DURABLE TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINATION
    Publication number: 20140206728
    Abstract: Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS.
    Type: Application
    Filed: March 21, 2014
    Publication date: July 24, 2014
    Applicant: ACORDA THERAPEUTICS, INC.
    Inventors: Andrew R. Blight, Ron Cohen
  • Sustained release aminopyridine composition
    Patent number: 8663685
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: March 4, 2014
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
    Publication number: 20130330277
    Abstract: Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 12, 2013
    Applicant: ACORDA THERAPEUTICS, INC.
    Inventors: Andrew R. Blight, Ron Cohen
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20130310426
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: July 24, 2013
    Publication date: November 21, 2013
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • DURABLE TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINATION
    Publication number: 20130267566
    Abstract: Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS.
    Type: Application
    Filed: September 6, 2010
    Publication date: October 10, 2013
    Inventors: Andrew R. Blight, Ron Cohen
  • Sustained release aminopyridine composition
    Patent number: 8551523
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: October 8, 2013
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • Methods of using sustained release aminopyridine compositions
    Patent number: 8440703
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: May 14, 2013
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
    Publication number: 20130072527
    Abstract: Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS.
    Type: Application
    Filed: July 5, 2012
    Publication date: March 21, 2013
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients With Demyelinating and Other Nervous System Conditions
    Publication number: 20130053420
    Abstract: Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.
    Type: Application
    Filed: August 11, 2010
    Publication date: February 28, 2013
    Inventors: Thomas C. Wessel, Andrew R. Blight
  • Method of using sustained release aminopyridine compositions
    Patent number: 8354437
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: January 15, 2013
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
    Publication number: 20120164078
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Application
    Filed: March 2, 2012
    Publication date: June 28, 2012
    Inventors: Andrew R. Blight, Lawrence Maranucci, Ron Cohen
  • METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
    Publication number: 20120064007
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Application
    Filed: November 18, 2011
    Publication date: March 15, 2012
    Inventors: Andrew R. Blight, Lawrence Maranucci, Ron Cohen
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20120041034
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: July 20, 2011
    Publication date: February 16, 2012
    Inventors: Andrew R. Blight, Ron Cohen
  • COMPOSITIONS AND METHODS FOR EXTENDED THERAPY WITH AMINOPYRIDINES
    Publication number: 20120029035
    Abstract: Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis.
    Type: Application
    Filed: February 11, 2010
    Publication date: February 2, 2012
    Applicant: ACORDA THERAPEUTICS, INC.
    Inventors: Andrew R. Blight, Ron Cohen
  • Sustained release aminopyridine composition
    Patent number: 8007826
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: August 30, 2011
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
    Publication number: 20110166187
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Application
    Filed: June 25, 2010
    Publication date: July 7, 2011
    Inventors: Andrew R. Blight, Ron Cohen
  • METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
    Publication number: 20110166189
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Application
    Filed: June 25, 2010
    Publication date: July 7, 2011
    Inventors: Andrew R. BLIGHT, Ron COHEN
  • METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
    Publication number: 20110166188
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Application
    Filed: June 25, 2010
    Publication date: July 7, 2011
    Inventors: Andrew R. BLIGHT, Ron COHEN